Evaluation of resectability after neoadjuvant chemotherapy for primary non-resectable colorectal liver metastases: A multicenter study

KYUSHU STUDY GROUP OF CLINICAL CANCER (KSCC)

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background/Aim The Kyushu Study Group of Clinical Cancer (KSCC) previously reported the safety and efficacy of neoadjuvant chemotherapy with mFOLFOX6 + bevacizumab for H2/H3 liver metastases of colorectal cancer. The aim of the current study was to evaluate the resectability of these metastases before and after chemotherapy as determined by independent liver surgeons. Methods Between May 2008 and April 2010, 40 patients were registered in a multicenter phase 2 trial of neoadjuvant chemotherapy (KSCC 0802). In Study 1, 5 independent liver surgeons from five different KSCC centers evaluated the resectability of liver metastases of colorectal cancer based on imaging studies performed before and after chemotherapy. Each surgeon was blinded to the other surgeons' evaluations. In addition, no information about the patients' characteristics was provided. In Study 2, 3 surgeons evaluated the resectability of these lesions based on imaging studies with discussion with each other, with the surgeons being provided with information on the patients' characteristics. Results In Study 1, 13 patients (36.1%) were evaluated to be resectable at baseline, whereas 17 patients (47.2%) were evaluated to be resectable after chemotherapy. In Study 2, 4 patients (11.1%) were evaluated to be resectable at baseline, compared to 23 patients (63.9%) after chemotherapy. Conclusion Neoadjuvant chemotherapy with mFOLFOX6 + bevacizumab was confirmed to increase the resectability of non-resectable liver metastases of colorectal cancer according to the independent assessments of surgeons.

Original languageEnglish
Pages (from-to)184-189
Number of pages6
JournalEuropean Journal of Surgical Oncology
Volume42
Issue number2
DOIs
Publication statusPublished - Feb 1 2016

Fingerprint

Multicenter Studies
Neoplasm Metastasis
Drug Therapy
Liver
Colorectal Neoplasms
Neoplasms
Surgeons
Safety
Clinical Studies

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Evaluation of resectability after neoadjuvant chemotherapy for primary non-resectable colorectal liver metastases : A multicenter study. / KYUSHU STUDY GROUP OF CLINICAL CANCER (KSCC).

In: European Journal of Surgical Oncology, Vol. 42, No. 2, 01.02.2016, p. 184-189.

Research output: Contribution to journalArticle

@article{02c6ea9ecfde4be194fbff057d8be4b3,
title = "Evaluation of resectability after neoadjuvant chemotherapy for primary non-resectable colorectal liver metastases: A multicenter study",
abstract = "Background/Aim The Kyushu Study Group of Clinical Cancer (KSCC) previously reported the safety and efficacy of neoadjuvant chemotherapy with mFOLFOX6 + bevacizumab for H2/H3 liver metastases of colorectal cancer. The aim of the current study was to evaluate the resectability of these metastases before and after chemotherapy as determined by independent liver surgeons. Methods Between May 2008 and April 2010, 40 patients were registered in a multicenter phase 2 trial of neoadjuvant chemotherapy (KSCC 0802). In Study 1, 5 independent liver surgeons from five different KSCC centers evaluated the resectability of liver metastases of colorectal cancer based on imaging studies performed before and after chemotherapy. Each surgeon was blinded to the other surgeons' evaluations. In addition, no information about the patients' characteristics was provided. In Study 2, 3 surgeons evaluated the resectability of these lesions based on imaging studies with discussion with each other, with the surgeons being provided with information on the patients' characteristics. Results In Study 1, 13 patients (36.1{\%}) were evaluated to be resectable at baseline, whereas 17 patients (47.2{\%}) were evaluated to be resectable after chemotherapy. In Study 2, 4 patients (11.1{\%}) were evaluated to be resectable at baseline, compared to 23 patients (63.9{\%}) after chemotherapy. Conclusion Neoadjuvant chemotherapy with mFOLFOX6 + bevacizumab was confirmed to increase the resectability of non-resectable liver metastases of colorectal cancer according to the independent assessments of surgeons.",
author = "{KYUSHU STUDY GROUP OF CLINICAL CANCER (KSCC)} and M. Takatsuki and S. Tokunaga and S. Uchida and M. Sakoda and K. Shirabe and T. Beppu and Y. Emi and Eiji Oki and S. Ueno and S. Eguchi and Y. Akagi and Y. Ogata and H. Baba and S. Natsugoe and Y. Maehara",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.ejso.2015.11.007",
language = "English",
volume = "42",
pages = "184--189",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Evaluation of resectability after neoadjuvant chemotherapy for primary non-resectable colorectal liver metastases

T2 - A multicenter study

AU - KYUSHU STUDY GROUP OF CLINICAL CANCER (KSCC)

AU - Takatsuki, M.

AU - Tokunaga, S.

AU - Uchida, S.

AU - Sakoda, M.

AU - Shirabe, K.

AU - Beppu, T.

AU - Emi, Y.

AU - Oki, Eiji

AU - Ueno, S.

AU - Eguchi, S.

AU - Akagi, Y.

AU - Ogata, Y.

AU - Baba, H.

AU - Natsugoe, S.

AU - Maehara, Y.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Background/Aim The Kyushu Study Group of Clinical Cancer (KSCC) previously reported the safety and efficacy of neoadjuvant chemotherapy with mFOLFOX6 + bevacizumab for H2/H3 liver metastases of colorectal cancer. The aim of the current study was to evaluate the resectability of these metastases before and after chemotherapy as determined by independent liver surgeons. Methods Between May 2008 and April 2010, 40 patients were registered in a multicenter phase 2 trial of neoadjuvant chemotherapy (KSCC 0802). In Study 1, 5 independent liver surgeons from five different KSCC centers evaluated the resectability of liver metastases of colorectal cancer based on imaging studies performed before and after chemotherapy. Each surgeon was blinded to the other surgeons' evaluations. In addition, no information about the patients' characteristics was provided. In Study 2, 3 surgeons evaluated the resectability of these lesions based on imaging studies with discussion with each other, with the surgeons being provided with information on the patients' characteristics. Results In Study 1, 13 patients (36.1%) were evaluated to be resectable at baseline, whereas 17 patients (47.2%) were evaluated to be resectable after chemotherapy. In Study 2, 4 patients (11.1%) were evaluated to be resectable at baseline, compared to 23 patients (63.9%) after chemotherapy. Conclusion Neoadjuvant chemotherapy with mFOLFOX6 + bevacizumab was confirmed to increase the resectability of non-resectable liver metastases of colorectal cancer according to the independent assessments of surgeons.

AB - Background/Aim The Kyushu Study Group of Clinical Cancer (KSCC) previously reported the safety and efficacy of neoadjuvant chemotherapy with mFOLFOX6 + bevacizumab for H2/H3 liver metastases of colorectal cancer. The aim of the current study was to evaluate the resectability of these metastases before and after chemotherapy as determined by independent liver surgeons. Methods Between May 2008 and April 2010, 40 patients were registered in a multicenter phase 2 trial of neoadjuvant chemotherapy (KSCC 0802). In Study 1, 5 independent liver surgeons from five different KSCC centers evaluated the resectability of liver metastases of colorectal cancer based on imaging studies performed before and after chemotherapy. Each surgeon was blinded to the other surgeons' evaluations. In addition, no information about the patients' characteristics was provided. In Study 2, 3 surgeons evaluated the resectability of these lesions based on imaging studies with discussion with each other, with the surgeons being provided with information on the patients' characteristics. Results In Study 1, 13 patients (36.1%) were evaluated to be resectable at baseline, whereas 17 patients (47.2%) were evaluated to be resectable after chemotherapy. In Study 2, 4 patients (11.1%) were evaluated to be resectable at baseline, compared to 23 patients (63.9%) after chemotherapy. Conclusion Neoadjuvant chemotherapy with mFOLFOX6 + bevacizumab was confirmed to increase the resectability of non-resectable liver metastases of colorectal cancer according to the independent assessments of surgeons.

UR - http://www.scopus.com/inward/record.url?scp=84955237683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955237683&partnerID=8YFLogxK

U2 - 10.1016/j.ejso.2015.11.007

DO - 10.1016/j.ejso.2015.11.007

M3 - Article

C2 - 26683263

AN - SCOPUS:84955237683

VL - 42

SP - 184

EP - 189

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 2

ER -